Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335514 | 0.85 | SLC6A4 (0.38) | ALDH1A1SLC6A4AOC3MEN1HBB | |
| SCHEMBL705925 | 0.84 | RIPK1 (0.34) | ALDH1A1SLC6A4AOC3MEN1HBB | |
| SCHEMBL7892375 | 0.82 | ALDH1A1 (0.34) | ALDH1A1SLC6A4AOC3MEN1HBB | |
| SCHEMBL15219237 | 0.81 | SMYD2 (0.34) | ALDH1A1SLC6A4AOC3SLC6A3RIPK1 | |
| SCHEMBL7503724 | 0.81 | ALDH1A1 (0.38) | ALDH1A1SLC6A4AOC3SLC6A2SLC6A3 | |
| SCHEMBL7354376 | 0.81 | CYP3A4 (0.33) | ALDH1A1SLC6A4AOC3SLC6A2SLC6A3 | |
| SCHEMBL28549734 | 0.81 | CYP3A4 (0.33) | ALDH1A1SLC6A4AOC3SLC6A3RIPK1 | |
| SCHEMBL9232886 | 0.81 | SMYD2 (0.34) | ALDH1A1SLC6A4AOC3SLC6A3RIPK1 | |
| SCHEMBL29086735 | 0.81 | CYP3A4 (0.33) | ALDH1A1SLC6A4AOC3SLC6A3RIPK1 | |
| SCHEMBL19513655 | 0.81 | CYP3A4 (0.33) | ALDH1A1SLC6A4AOC3SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938297-B2 | Process for the synthesis of everolimus and intermediates thereof | Cipia Limited (IN) | 2018-04-10 | — | — | US | claimed |
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | CIPLA LIMITED (IN) | 2017-08-03 | — | — | US | claimed |
| EP-3166950-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | Cipla Limited (IN) | 2017-05-17 | — | — | EP | claimed |
| WO-2016020664-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2016-02-11 | — | — | WO | claimed |
| WO-2021113665-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-9938297-B2 | Process for the synthesis of everolimus and intermediates thereof | Cipia Limited (IN) | 2018-04-10 | — | — | US | disclosed |
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | CIPLA LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
| EP-3166950-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | Cipla Limited (IN) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016020664-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | MTOR, RICTOR, RPTOR | ALDH1A1 2765/4885SLC6A4 3052/4885AOC3 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.